PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 14, 2026Antimicrobial Agents and Chemotherapy0 citationsOpen Access

In vivo selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing E. coli ST410

AJAgnès B. JoussetDGDelphine GirlichSOSaoussen Oueslati

Key Points

  • The aim is to investigate the emergence of CMY-219, a resistance variant, to ceftazidime-avibactam in E. coli ST410.
  • In vivo selection of ESBL-producing E. coli ST410
  • Treatment with ceftazidime-avibactam
  • Molecular analysis of resistance mechanisms
  • Identification of CMY-219 variant after treatment exposure
  • CMY-219 was associated with high-level resistance to ceftazidime-avibactam
  • Concerns raised about the ability of ST410 and related clones to develop resistance quickly

Abstract

ABSTRACT Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing Escherichia coli ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jousset et al. (2026) studied this question.

synapsesocial.com/papers/699011032ccff479cfe576c1https://doi.org/10.1128/aac.01335-25
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<i>In vitro</i> activity of ceftazidime–avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 20202024 · 1 citations
  2. 2Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis2024 · 1 citations
  3. 3In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-22026
  4. 4In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019–20212024 · 2 citations
  5. 5LONGITUDINAL ANALYSIS (2018 TO 2023) OF THE IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AGAINST CLINICAL ISOLATES OF KLEBSIELLA PNEUMONIAE COLLECTED FROM BRAZILIAN CENTERS FOR THE ATLAS SURVEILLANCE PROGRAM2026